Skip to main content
PMC home page
AAPS PharmSci logoLink to AAPS PharmSci
. 2015 Jul 10;6(1):45–56. doi: 10.1208/ps060105

Preparation, characterization, and biodistribution study of technetium-99m-labeled leuprolide acetate-loaded liposomes in ehrlich ascites tumor-bearing mice

N Arulsudar 1, N Subramanian 1, P Mishra 2, K Chuttani 2, R K Sharma 2, R S R Murthy 1,✉
PMCID: PMC2750940  PMID: 15198506

Abstract

The purpose of this study was to prepare conventional and sterically stabilized liposomes containing leuprolide acetate in an attempt to prolong the biological half life of the drug, to reduce the uptake by reticuloendothelial system (RES), and to reduce the injection frequency of intravenously administered peptide drugs. The conventional and sterically stabilized liposomes containing leuprolide acetate were prepared by reverse phase evaporation method and characterized for entrapment efficiency and particle size. Radiolabeling of leuprolide acetate and its liposomes was performed by direct labeling with reduced technetium-99m. Its biodistribution and imaging characteristics were studied in ehrlich ascites tumor (EAT)-bearing mice after labeling with technetium-99m. The systemic pharmacokinetic studies were performed in rabbits. A high uptake by tumor was observed by sterically stabilized liposome containing leuprolide acetate compared with free drug and conventional liposomes. The liver/tumor uptake ratio of free drug, conventional (LL), and sterically stabilized liposomes (SLL5000 and SLL2000) was found to be 20, 7.99, 1.63, and 1.23, respectively, which showed the increased accumulation of sterically stabilized liposomes in tumor compared with the free drug and conventional liposomes at 24 hours postinjection. Liver uptake of sterically stabilized liposomes was still 7-fold less than the conventional liposomes. The marked accumulation of liposomes in the tumor-bearing mice was also documented by gamma scintigraphic studies. The findings demonstrate the distribution of these liposomes within solid tumor and prove that the sterically stabilized liposomes experience increased tumor uptake and prolonged circulation half life. Hence these findings will be relevant for the optimal design of long circulating liposomes for the peptide drugs and for targeting of liposomes toward tumor.

Keywords: sterically stabilized liposomes, leuprolide acetate, technetium-99m, biodistribution, gamma imaging

References

  • 1.Chrisp P, Sorkin EM. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging. 1991;1:487–509. doi: 10.2165/00002512-199101060-00008. [DOI] [PubMed] [Google Scholar]
  • 2.Oesterling JE. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia. J Androl. 1991;12:381–388. [PubMed] [Google Scholar]
  • 3.Tunn UW, Bargelloni U, Cosciani S, Guazzieris Fiacavento G, Pagano F. Comparison of LHRH analogue 1 month depot and 3-month depot by their hormonal levels and pharmacokinetic profile in patients with advance prostate cancer. Urol Int. 1998;60(suppl 1):9–16. doi: 10.1159/000056540. [DOI] [PubMed] [Google Scholar]
  • 4.Plosker GL, Brodgen RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostate cancer, endometriosis and other sex hormone related disorders. Drugs. 1994;48(6):930–967. doi: 10.2165/00003495-199448060-00008. [DOI] [PubMed] [Google Scholar]
  • 5.Garnick MB. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311:1281–1286. doi: 10.1056/NEJM198411153112004. [DOI] [PubMed] [Google Scholar]
  • 6.Okada H, Sakura Y, Kawaji T, Yashiki T, Mima H. Regression of rat mammary tumors by a potent leutinizing hormone releasing hormone administered vaginally. Cancer Res. 1983;43:1869–1874. [PubMed] [Google Scholar]
  • 7.Redding TW, Schally AV. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of LHRH. Proc Natl Acad Sci U S A. 1981;78:6509–6512. doi: 10.1073/pnas.78.10.6509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Nagai N, Oshita T, Mukai K, Shiroyama Y, Shigemasa K, Ohama K. GnRH agonist inhibits human telomerase reverse transcriptase mRNA expression in endometrial cancer cells. Int J Mol Med. 2002;10:593–597. [PubMed] [Google Scholar]
  • 9.Dondi D, Limnota P, Moretti RM, Marelli MM, Garattini E, Mota M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen independent prostate cancer cell line DU145: evidence for an autocrine-inhibitory loop. Cancer Res. 1994;54:4091–4095. [PubMed] [Google Scholar]
  • 10.Limonta P, Dondi D, Moretti RM, Maggi R, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab. 1992;75:207–212. doi: 10.1210/jcem.75.1.1320049. [DOI] [PubMed] [Google Scholar]
  • 11.Dondi D, Moretti RM, Marelli MM, et al. Growth inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer. 1998;76:506–511. doi: 10.1002/(SICI)1097-0215(19980518)76:4<506::AID-IJC11>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  • 12.Schally AV. Hypothalamic hormones from neuroendocrinology to cancer therapy. Anticancer Drugs. 1994;5:115–130. doi: 10.1097/00001813-199404000-00001. [DOI] [PubMed] [Google Scholar]
  • 13.Loop SM, Gorder CA, Lewis SM, Saiers JH, Drivdahl RH, Ostenson RC. Growth inhibition of human prostatic cancer cells by an agonist of gonadotropin-releasing hormone. Prostate. 1995;26:179–188. doi: 10.1002/pros.2990260403. [DOI] [PubMed] [Google Scholar]
  • 14.Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumor receptors. Br J Cancer. 1990;62:96–99. doi: 10.1038/bjc.1990.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol. 1994;106:145–149. doi: 10.1016/0303-7207(94)90196-1. [DOI] [PubMed] [Google Scholar]
  • 16.Anderson PM, Hanson DC, Hasz DE, Halet MR, Blazar BR, Ochoa AC. Cytokines in liposomes: Preliminary studies with IL-1, IL-2, IL-6, GM-CSF and Interferon Gamma. Cytokine. 1994;6:92–101. doi: 10.1016/1043-4666(94)90014-0. [DOI] [PubMed] [Google Scholar]
  • 17.Meyer J, Whitcomb L, Collins D. Efficient encapsulation of proteins within liposomes for slow release in vivo. Biochem Biophys Res Commun. 1994;199:433–438. doi: 10.1006/bbrc.1994.1247. [DOI] [PubMed] [Google Scholar]
  • 18.Perez-Soler R. Liposomes as carriers of antitumor agents; towards a clinical reality. Cancer Treat Rev. 1989;16:67–82. doi: 10.1016/0305-7372(89)90011-X. [DOI] [PubMed] [Google Scholar]
  • 19.Gabizon A. Liposomes as a drug delivery system in cancer chemotherapy. In: Roerdink F, Kroon A, editors. Drug Carrier Systems, Horizons in Biochemistry and Biophysics. New York, NY: John Wiley & Sons; 1989. pp. 185–211. [PubMed] [Google Scholar]
  • 20.Gabizon AA, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst. 1989;81:1484–1488. doi: 10.1093/jnci/81.19.1484. [DOI] [PubMed] [Google Scholar]
  • 21.Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992;52:6774–6781. [PubMed] [Google Scholar]
  • 22.Allen TM, Hansen C, Martin F, Redemann C, Yan-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in-vivo. Biochim Biophys Acta. 1991;1066:29–36. doi: 10.1016/0005-2736(91)90246-5. [DOI] [PubMed] [Google Scholar]
  • 23.Allen TM, Mehra T, Hansen C, Chin YC. Stealth liposomes: and improved sustained release system for 1-beta-D arabinofuranosylcytosine. Cancer Res. 1992;52:2431–2439. [PubMed] [Google Scholar]
  • 24.Allen TA, Hansen C. Pharmacokinetics of stealth vs. conventional liposomes: Effect of dose. Biochim Biophys Acta. 1991;1068:133–141. doi: 10.1016/0005-2736(91)90201-I. [DOI] [PubMed] [Google Scholar]
  • 25.Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse evaporation. Proc Natl Acad Sci U S A. 1978;75:4194–4198. doi: 10.1073/pnas.75.9.4194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.New RRC. Liposomes: a practical approach. In: New RRC, editor. Preparation of Liposomes. New York, NY: Oxford University Press; 1990. pp. 95–96. [Google Scholar]
  • 27.Adjei AL, Hsu L. Leuprolide and other LHRH analogues. In: John YW, Pearlman R, editors. Stability and Characterization of Protein and Peptide Drugs. New York, NY: Plenum Press; 1993. pp. 154–180. [Google Scholar]
  • 28.Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  • 29.Richardson VJ, Jeyasingh K, Jewkes RF. Properties of [99mTc] technetium-labeled liposomes in normal and tumour-bearing rats. Biochem Soc Trans. 1977;5(1):290–229. doi: 10.1042/bst0050290. [DOI] [PubMed] [Google Scholar]
  • 30.Theobald AE. Theory and practice. In: Sampson CB, editor. Textbook of Radiopharmacy. New York, NY: Gorden and Breach; 1990. pp. 127–128. [Google Scholar]
  • 31.Wu MS, Robbins JC, Ponpipom MM, Shen TV. Modified in vivo behaviour of liposomes containing synthetic glycolipids. Biochim Biophys Acta. 1981;674:19–29. doi: 10.1016/0304-4165(81)90342-1. [DOI] [PubMed] [Google Scholar]
  • 32.Lo Y, Rahman Y. Protein location in liposomes, a drug carrier: a prediction by differential scanning calorimetry. J Pharm Sci. 1995;84:805–813. doi: 10.1002/jps.2600840705. [DOI] [PubMed] [Google Scholar]
  • 33.Schafer H, Schmidt W, Lachmann U. Preparation and properties of GnRh-loaded multilamellar liposomes. Pharmazie. 1987;42:674–677. [PubMed] [Google Scholar]
  • 34.Huang L. Covalently attached polymers and glycans to alter the biodistribution of liposomes. J Liposome Res. 1992;2:289–291. doi: 10.3109/08982109209010224. [DOI] [Google Scholar]
  • 35.Litzinger CD, Buiting MJA, Rooijen VN, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta. 1994;1190:99–107. doi: 10.1016/0005-2736(94)90038-8. [DOI] [PubMed] [Google Scholar]
  • 36.Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235–237. doi: 10.1016/0014-5793(90)81016-H. [DOI] [PubMed] [Google Scholar]
  • 37.Saha GB. Methods of radiolabeling. In: Saha GB, editor. Physics and Radiobiology of Nuclear Medicine. New York, NY: Springer-Verlag; 1993. pp. 100–106. [Google Scholar]
  • 38.Gabizon G, Papahadjopoulos D. Liposome formulation with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988;85:6949–6953. doi: 10.1073/pnas.85.18.6949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gabizon G, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Cancer Res. 1994;54:987–992. [PubMed] [Google Scholar]
  • 40.Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9:253–256. doi: 10.1007/BF00046364. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSci are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES